Remote delivery of a therapeutic intervention to court-mandated youths of Haitian descent during COVID-19.
Remote delivery of a therapeutic intervention to court-mandated youths of Haitian descent during COVID-19.
复制标题
在新冠肺炎 (COVID-19) 疫情期间，向法院授权的海地裔青少年远程提供治疗干预。
DOI：
10.1002/jcop.22559
复制
发表时间：
2021
影响因子：
2.3
通讯作者：
Waldman,Rachel
中科院分区：
文献类型：
--
作者：
Marcelin,LouisHerns;Cela,Toni;Dembo,Richard;Jean-Gilles,Michèle;Page,Bryan;Demezier,Danna;Clement,Roy;Waldman,Rachel
COVID - 19大流行带来的威胁引发了突然的制度变革，以减少病毒传播。对集体聚会和面对面接触的限制增加了对远程服务提供的需求。这些限制也影响了法院强制干预措施的实施。然而，大部分文献都集中在自愿寻求面对面医疗或心理健康服务的人群上，而对法院强制人群的远程医疗参与关注不足。本文利用了在COVID - 19公共卫生危机期间，在佛罗里达州迈阿密-戴德县对涉及少年司法的海地裔青少年进行的一项NIH/NIDA资助的研究干预中收集的数据。我们探讨了获得同意的过程，技术访问问题，管理隐私，以及与远程提供基于家庭的治疗相关的其他挑战。我们的目的是提供一些见解，供治疗师、卫生保健工作者、倡导者、研究人员和决策者考虑，他们的任务是寻找替代的、更安全的方式，让非传统人群参与卫生服务。临床试验注册号为NCT03876171。
The threat generated by the COVID‐19 pandemic has triggered sudden institutional changes in an effort to reduce viral spread. Restrictions on group gatherings and in‐person engagement have increased the demand for remote service delivery. These restrictions have also affected the delivery of court‐mandated interventions. However, much of the literature has focused on populations that voluntarily seek out face‐to‐face medical care or mental health services, whereas insufficient attention has been paid to telehealth engagement of court‐mandated populations. This article draws on data gathered on an NIH/NIDA‐funded study intervention implemented with juvenile justice‐involved youths of Haitian heritage in Miami‐Dade County, Florida, during the COVID‐19 public health crisis. We explore the process of obtaining consent, technological access issues, managing privacy, and other challenges associated with remote delivery of family‐based therapy to juvenile justice‐involved youth. Our aim is to provide some insights for consideration by therapists, healthcare workers, advocates, researchers, and policymakers tasked with finding alternative and safer ways to engage nontraditional populations in health services. The clinical trial registration number is NCT03876171.